Biotech stories
Rising demand for board-level hires in the UK and US has prompted the search firm to expand specialist coverage after client demand jumped 120%.
A crowded oncology technology market stands to gain a new rival as the Boston-based start-up targets continuous monitoring for 40 million high-risk Americans.
The Auckland start-up will use the funds to develop capsules for microgravity research and manufacturing as demand grows for orbital access.
Better process visibility could help the Danish drugmaker shave 12 months or more off development, bringing medicines to patients sooner.
European firms needing secure, low-carbon compute gain a bigger home as the deal expands cloud, AI and dedicated HPC services under one roof.
Food and agriculture start-ups may see fresh capital as the firm targets software and biology plays after the sector's sharp funding pullback.
The shortlist highlights UK startups in biotech, energy, health and AI as investors and buyers look for scalable technology beyond Cambridge.
The shortlist spans software, biotech and retail, highlighting the breadth of New Zealand firms vying for EY's 2026 entrepreneur prize.
Singapore retail investors get broader access to Asian and thematic funds as demand shifts towards technology and diversification.
The relocation gives the RuneScape maker a larger, sustainable base as Cambridge landlords court more than just life science tenants.
AI startups drove 57% of UK equity funding by value in Q2, as eight large rounds accounted for almost 80% of disclosed investment.
Most fintech startups could miss out on planned tax relief unless Treasury rewrites rules to reflect the sector's long, costly path to scale.
Recruitment delays at Canopy's sites could ease as a dedicated platform is set to cut missed follow-ups and lift enrolment rates.
Healthcare and AI start-ups dominate the shortlist, as investors prepare to hear pitches from firms tackling accessibility, childcare and drug delivery.
AI specialists are still a minority, but their rapid sales growth signals Britain's scale-up market is broadening beyond traditional sectors.
The move gives the campus its first commercial occupier for The Sequence and adds 21,000 sq ft of labs for health start-ups.
Investor demand for Australian startups is outpacing funding channels, with only 27% willing to commit more than AUD $100,000 to one deal.
The advisory body is meant to steer an expanded Cambridge site aiming to house 9,000 people and about 250 life sciences companies by 2028.
The hub's second year delivered a 21% rise in output, with independent analysis showing it supported 148 jobs across Wellington.
Five days of talks in Cambridge will focus on how deep tech can scale internationally, with energy, AI and investment leaders set to attend.
